NASDAQ:IOSP - Innospec Stock Price, Forecast & News

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec announced a Semi-Annual dividend on Tuesday, November 5th. Shareholders of record on Tuesday, November 19th will be paid a dividend of $0.52 per share on Wednesday, November 27th. The ex-dividend date of this dividend is Monday, November 18th. This is a boost from Innospec's previous Semi-Annual dividend of $0.50. View Innospec's Dividend History.

Innospec Inc. (NASDAQ:IOSP) posted its earnings results on Tuesday, February, 18th. The specialty chemicals company reported $1.47 EPS for the quarter, topping the Zacks' consensus estimate of $1.38 by $0.09. The specialty chemicals company had revenue of $390.70 million for the quarter, compared to analysts' expectations of $400.45 million. Innospec had a return on equity of 14.69% and a net margin of 7.41%. Innospec's revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.62 EPS. View Innospec's Earnings History.

Innospec is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Innospec.

1 Wall Street analysts have issued 12 month price targets for Innospec's shares. Their forecasts range from $95.00 to $95.00. On average, they anticipate Innospec's share price to reach $95.00 in the next twelve months. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for Innospec.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innospec.

Press coverage about IOSP stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innospec earned a news impact score of -1.7 on InfoTrie's scale. They also assigned media stories about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Innospec.

Innospec saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 391,900 shares, an increase of 6.7% from the January 15th total of 367,400 shares. Based on an average daily volume of 98,700 shares, the short-interest ratio is currently 4.0 days. Currently, 1.6% of the company's stock are short sold. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Ecolab (ECL), Sherwin-Williams (SHW), International Flavors & Fragrances (IFF), Celanese (CE), RPM International (RPM), Albemarle (ALB), NewMarket (NEU), Ashland Global (ASH), W. R. Grace & Co (GRA), Quaker Chemical (KWR), Balchem (BCPC), PolyOne (POL), HB Fuller (FUL), Sensient Technologies (SXT) and Stepan (SCL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Intellia Therapeutics (NTLA), Las Vegas Sands (LVS), Altria Group (MO), Exxon Mobil (XOM), NVIDIA (NVDA), Franklin Resources (BEN), Colgate-Palmolive (CL), Eastman Chemical (EMN), Emerson Electric (EMR) and Invesco (IVZ).

Innospec's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (11.72%), State Street Corp (2.90%), Champlain Investment Partners LLC (2.71%), Royce & Associates LP (2.42%), Geode Capital Management LLC (1.47%) and Bank of New York Mellon Corp (1.25%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Institutional Ownership Trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., First Wilshire Securities Management Inc., NWQ Investment Management Company LLC, Bank of New York Mellon Corp, Royce & Associates LP, Westwood Holdings Group Inc. and SG Americas Securities LLC. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Patrick Williams, Philip Curran and Philip John Boon. View Insider Buying and Selling for Innospec.

IOSP stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, James Investment Research Inc., Thrivent Financial for Lutherans, Great West Life Assurance Co. Can, Bank of Montreal Can, Citigroup Inc., Mackay Shields LLC and First Trust Advisors LP. View Insider Buying and Selling for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $84.28.

Innospec has a market capitalization of $2.07 billion and generates $1.51 billion in revenue each year. Innospec employs 2,000 workers across the globe.View Additional Information About Innospec.

The official website for Innospec is http://www.innospecinc.com/.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]